Chai Discovery | $70,000,000 | (Aug 7, 2025)
Xovian Aerospace | $2,500,000 | (Aug 7, 2025)
Elion | $9,300,000 | (Aug 7, 2025)
ImmuneWalk Therapeutics
United States
- Pearl River, New York
- 08/05/2025
- Seed
- $7,000,000
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.
- Industry Biotechnology Research
- Website https://immunewalk.com/
- LinkedIn https://www.linkedin.com/company/immunewalk-therapeutics/
August | $7,000,000 | (Aug 7, 2025)
Stavtar Solutions | $55,000,000 | (Aug 7, 2025)
Tavily | $25,000,000 | (Aug 7, 2025)
Clay | $100,000,000 | (Aug 7, 2025)
Tracelight | $3,600,000 | (Aug 7, 2025)
CodeKarma | $2,500,000 | (Aug 7, 2025)
WiseBee | $2,444,263 | (Aug 7, 2025)
Positive Development | $51,500,000 | (Aug 7, 2025)
Vendict | $10,000,000 | (Aug 6, 2025)